• HOME
• ABOUT US
  • Company Profile
  • CRO's & Pharmaceutical Companies
• COMPANY BIOS
  • Jeff Stein
  • David M. Radin, MD
  • Judith Dalgin
  • Svetlana Konnov, LPN
  • Betsy Kempner, RN
  • Patrick Brew, MD, RN
  • Tulie Brew, MD
  • Anju Sherstha, MD
• CURRENT TRIALS
  • Chronic Lower Back Pain
  • Chronic Pain
  • Interstitial Cystitis / Painful Bladder Syndrome
  • Osteoarthritis
• CONDITIONS
• CONTACT US

Osteoarthritis

Stamford Therapeutics Consortium is currently conducting a Phase III study on osteoarthritis of the hip or knee sponsored by Pfizer.

Summary: The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis.

For More Information Please Contact:
Judy Dalgin (Site Manager)
email: jdalgin@stctrials.com
telephone: 203-325-8529


Eligibility:

• Ages Eligible for Study: 18 Years to 75 Years

• Genders Eligible for Study: Both

• Accepts Healthy Volunteers: No


Inclusion Criteria:

• Osteoarthritis of the knee or hip according to Kellgren-Lawrence x-ray grade of 2


Exclusion Criteria:

• Pregnancy or intent to become pregnant

• BMI greater than 39

• Other severe pain, significant cardiac, neurological or psychiatric disease